Patent 7189562 was granted and assigned to Oxford Biomedica (UK) Limited on March, 2007 by the United States Patent and Trademark Office.
The invention relates to the exploitation of the migratory behavior of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the munonuclear phagocyte to a target area.